Keywords: مقاومت به ایموتینیب; przewlekła białaczka szpikowa; oporność na imatynib; dazatynib; nilotynibChronic myeloid leukemia; Imatinib resistance; Nilotinib; Dasatinib
مقالات ISI مقاومت به ایموتینیب (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: مقاومت به ایموتینیب; BCRP, breast cancer related protein; CML, chronic myeloid leukemia; IMA, Imatinib; P-gP, P-glycoprotein; OCT, organic cation transporter; TKI, tirosine kinase inhibitorCML; Imatinib resistance; Therapeutic interruptions; Membrane drug transporters; P-glyc
Analysis of ABL kinase domain mutations as a probable cause of imatinib resistance in Chronic Myeloid Leukemia patients of Kashmir
Keywords: مقاومت به ایموتینیب; Imatinib resistance; Fusion transcript; Kinase domain; cDNA; BCR-ABL; Complete cytogenetic response;
miR-125a-5p regulation increases phosphorylation of FAK that contributes to imatinib resistance in gastrointestinal stromal tumors
Keywords: مقاومت به ایموتینیب; GIST; gastrointestinal stromal tumor; PDGFRA; platelet-derived growth factor receptor A; pFAK; phosphorylated FAK; FAKi; FAK inhibitor 14; miRNA; microRNA; PTPN18; protein tyrosine phosphatase non-receptor type 18; miR-125a-5p; PTPN18; pFAK; Imatinib resi
Inducible SHP-2 activation confers resistance to imatinib in drug-tolerant chronic myeloid leukemia cells
Keywords: مقاومت به ایموتینیب; SHP-2 activation; CML; Imatinib resistance; RAF/MEK/ERK pathway; PI3K/AKT/mTOR pathway; Non-mutational drug resistance;
microRNA-199a/b-5p enhance imatinib efficacy via repressing WNT2 signaling-mediated protective autophagy in imatinib-resistant chronic myeloid leukemia cells
Keywords: مقاومت به ایموتینیب; Imatinib resistance; Autophagy; miR-199a-5p; miR-199b-5p; WNT2; Chronic myeloid leukemia (CML); 3-MA; 3-methyladenine; AVO; acidic vesicular organelle; CML; chronic myeloid leukemia; CQ; chloroquine; DMSO; dimethyl sulfoxide; HRP; horseradish peroxidase;
Influence of MDR1 and CYP3A5 genetic polymorphisms on trough levels and therapeutic response of imatinib in newly diagnosed patients with chronic myeloid leukemia
Keywords: مقاومت به ایموتینیب; Pharmacogenetics; P-glycoprotein; Imatinib resistance; Single nucleotide polymorphisms; Personalized medicine; Tyrosine kinase inhibitor;
MicroRNAs that affect the Fanconi Anemia/BRCA pathway are downregulated in imatinib-resistant chronic myeloid leukemia patients without detectable BCR-ABL kinase domain mutations
Keywords: مقاومت به ایموتینیب; Chronic myeloid leukemia; Imatinib resistance; miRNA-seq; Fanconi anemia; BRCA pathway;
EphB4-VAV1 signaling pathway is associated with imatinib resistance in chronic myeloid leukemia cells
Keywords: مقاومت به ایموتینیب; EphB4; VAV1; Chronic myeloid leukemia; Imatinib resistance;
Haploidentical Hematopoietic Stem Cell Transplantation without In Vitro T Cell Depletion for the Treatment of Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia
Keywords: مقاومت به ایموتینیب; Haploidentical; Hematopoietic stem cell transplantation; Philadelphia chromosome; Acute lymphoblastic leukemia; Imatinib resistance
Subcutaneous omacetaxine mepesuccinate in patients with chronic myeloid leukemia in tyrosine kinase inhibitor-resistant patients: Review and perspectives
Keywords: مقاومت به ایموتینیب; Chronic phase CML; Imatinib; Imatinib resistance; BCR-ABL mutation; T315I;
Frequency of ABL gene mutations in chronic myeloid leukemia patients resistant to imatinib and results of treatment switch to second-generation tyrosine kinase inhibitors
Keywords: مقاومت به ایموتینیب; Chronic myeloid leukemia; Imatinib resistance; ABL mutations; Clonal cytogenetic evolution; Second-generation tyrosine kinase inhibitors; Leucemia mieloide crónica; Resistencia a imatinib; Mutaciones de ABL; Evolución citogenética clonal; Inhibidores d
The study of resistant mechanisms and reversal in an imatinib resistant Ph+ acute lymphoblastic leukemia cell line
Keywords: مقاومت به ایموتینیب; Imatinib resistance; Ph+ acute lymphoblastic leukemia; Tyrosine kinase inhibitor; mTOR signaling pathway; Proteasome inhibitor
Epigenetic Therapy With Hydralazine and Magnesium Valproate Reverses Imatinib Resistance in Patients With Chronic Myeloid Leukemia
Keywords: مقاومت به ایموتینیب; Chronic myeloid leukemia; Epigenetic therapy; Imatinib resistance
Myc induced miR-144/451 contributes to the acquired imatinib resistance in chronic myelogenous leukemia cell K562
Keywords: مقاومت به ایموتینیب; miR-144/451; c-myc; Imatinib resistance; Chronic myelogenous leukemia;
BCR-ABL kinase domain mutations in tyrosine kinase inhibitors-naïve and -exposed Southeast Asian chronic myeloid leukemia patients
Keywords: مقاومت به ایموتینیب; Chronic myeloid leukemia; BCR-ABL; KD mutations; Imatinib resistance; Tyrosine kinase inhibitors; Southeast Asia
Pegylated IFN-α2a combined to imatinib mesylate 600 mg daily can induce complete cytogenetic and molecular responses in a subset of chronic phase CML patients refractory to IFN alone or to imatinib 600 mg daily alone
Keywords: مقاومت به ایموتینیب; CML; Imatinib resistance; Peg-Interferon; Philadelphia chromosome; BCR-ABL; BCR-ABL mutations
Genomic characterization of Imatinib resistance in CD34+ cell populations from chronic myeloid leukaemia patients
Keywords: مقاومت به ایموتینیب; Chronic myeloid leukaemia; Imatinib resistance; Genomic instability; CGH array
Acetylome and phosphoproteome modifications in imatinib resistant chronic myeloid leukaemia cells treated with valproic acid
Keywords: مقاومت به ایموتینیب; CML BCR/ABL; Proteomics; Imatinib resistance; Valproic acid; Protein phosphorylation; Protein acetylation;
A gene expression signature of primary resistance to imatinib in chronic myeloid leukemia
Keywords: مقاومت به ایموتینیب; Chronic myeloid leukemia; Imatinib resistance; DNA microarrays; Gene expression profiling; DNA repair;
Zinc-finger transcription factor slug contributes to the survival advantage of chronic myeloid leukemia cells
Keywords: مقاومت به ایموتینیب; Slug; Chronic myeloid leukemia; Apoptosis resistance; Imatinib resistance; ERK1/2; E-cadherin
Meta-analysis of microarray data: The case of imatinib resistance in chronic myelogenous leukemia
Keywords: مقاومت به ایموتینیب; Meta-analysis; Microarrays; Imatinib resistance; CML; Gene expression
Bosutinib: A review of preclinical studies in chronic myelogenous leukaemia
Keywords: مقاومت به ایموتینیب; Bosutinib; SKI-606; Chronic myelogenous leukaemia; Src; Bcr-Abl; Breast cancer; Tumour; Tyrosine kinase inhibitor; Imatinib resistance; Clinical trials
Inhibitors of the Abl kinase directed at either the ATP- or myristate-binding site
Keywords: مقاومت به ایموتینیب; Abl; Imatinib resistance; Myristate binders; Kinase inhibitors; Abl structure;
Circulating heat shock protein 70 and progression in patients with chronic myeloid leukemia
Keywords: مقاومت به ایموتینیب; Circulating heat shock protein; Chronic myeloid leukemia; Imatinib resistance
Imatinib resistance in CML
Keywords: مقاومت به ایموتینیب; Imatinib; Chronic myeloid leukaemia; Imatinib resistance
Overcoming kinase resistance in chronic myeloid leukemia
Keywords: مقاومت به ایموتینیب; Dasatinib; Imatinib resistance; BCR-ABL
FoxO tumor suppressors and BCR–ABL-induced leukemia: A matter of evasion of apoptosis
Keywords: مقاومت به ایموتینیب; Apoptosis; BCR–ABL; CML; FoxO; Imatinib resistance; Proteasomal degradation
Roots of imatinib resistance: A question of self-renewal?
Keywords: مقاومت به ایموتینیب; Imatinib resistance; CML; Ph+ ALL; BCR-ABL; Self-renewal; BCR-ABL independent drug resistance
Adaphostin and bortezomib induce oxidative injury and apoptosis in imatinib mesylate-resistant hematopoietic cells expressing mutant forms of Bcr/Abl
Keywords: مقاومت به ایموتینیب; Adaphostin; Bortezomib; ROS; Phospho-Bcr/Abl; Imatinib resistance
Assessment and follow-up of the proportion of T315I mutant BCR-ABL transcripts can guide appropriate therapeutic decision making in CML patients
Keywords: مقاومت به ایموتینیب; Chronic myelogenous leukemia; BCR-ABL mutations; T315I; Imatinib resistance;